Shattuck Labs Inc (NASDAQ: STTK) on Friday, plunged -16.36% from the previous trading day, before settling in for the closing price of $2.2. Within the past 52 weeks, STTK’s price has moved between $0.69 and $2.70.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.93%. The company achieved an average annual earnings per share of 52.48%. With a float of $45.15 million, this company’s outstanding shares have now reached $47.90 million.
Shattuck Labs Inc (STTK) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Shattuck Labs Inc is 28.51%, while institutional ownership is 44.78%. The most recent insider transaction that took place on Aug 25 ’25, was worth 5,471,826. In this transaction Director of this company bought 6,306,127 shares at a rate of $0.87, taking the stock ownership to the 5,255,106 shares. Before that another transaction happened on Aug 25 ’25, when Company’s Director bought 6,306,127 for $0.87, making the entire transaction worth $5,471,826. This insider now owns 5,255,106 shares in total.
Shattuck Labs Inc (STTK) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.33 earnings per share (EPS) for the period topping the consensus outlook (set at -0.42) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.86% during the next five years compared to -20.93% drop over the previous five years of trading.
Shattuck Labs Inc (NASDAQ: STTK) Trading Performance Indicators
Shattuck Labs Inc (STTK) is currently performing well based on its current performance indicators. A quick ratio of 10.25 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 38.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.52 in one year’s time.
